Islet Cell Transplantation Clinical Trials

Clinical trials related to Islet Cell Transplantation Procedure

SGLT2i Therapy in Islet Transplantation (SIT)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Age 18-70 years old;

• \>1 year after TPIAT date at enrollment;

• Partial islet function defined as stimulated C-peptide ≥0.6 ng/mL at screening/baseline visit, AND either (1) on insulin at ≤0.25 unit/kg/day OR (2) not on insulin but HbA1c \>6.5%;

• Stable diabetes management defined by stable on pump or multiple daily injections (MDI) for at least 8 weeks and \<25% change in insulin dosing over prior 8 weeks.

• Willing to manage diabetes medication management/dose adjustments for the duration of the study with study team MD

• Willing to wear continuous glucose monitor for diabetes management (currently standard of care for TPIAT diabetes)

• Willing to record insulin doses for 14 day intervals x 3 study visits.

• Willing and able to come to the UMN Clinical Research Unit for 3 study visits, approximately 3 months apart

• No prescribed medications other than insulin to treat diabetes in the past 4 weeks.

Locations
United States
Minnesota
University of Minnesota
RECRUITING
Minneapolis
Contact Information
Primary
Peggy Ptacek
vorwa001@umn.edu
612-626-5905
Time Frame
Start Date: 2026-07-21
Estimated Completion Date: 2028-12-01
Participants
Target number of participants: 40
Treatments
No_intervention: No Medication x 3 months, then 25 mg Empagliflozin x 3 months
Active_comparator: Empagliflozin 10 mg x 3 months, then 25 mg Empagliflozin x 3 months
Active_comparator: Empagliflozin 25 mg x 6 months
Sponsors
Leads: University of Minnesota

This content was sourced from clinicaltrials.gov